A clinical investigational study on safety and effective management of type-2 diabetes mellitus patients by using sitagliptin

Surendranath Behera, Siddharth Behera


Background: To study the health and efficiency of the more up to date oral hypoglycemic specialist sitagliptin in the executives of sort 2 diabetes mellitus patients. In our examination authors have enlisted 250 patients who met our investigation criteria of which authors ordered dependent on age and lab information, most of patients in the age bunch between 45-55 years (n=97, 39.2%), the RBS was diminished to Comparatively estimations of RBS, FBS, PPBS, HbA1C were decreased in follow up than benchmark esteem.

Methods: This simultaneous observational investigation was done when all is said in done department of General Medicine of Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha for a time of 6 months in which type 2 diabetes mellitus patients were enrolled dependent on incorporation and avoidance criteria and were pursued to assess the adequacy and security of sitagliptin. Information was dissected by utilizing chart cushion crystal understudy T-test.

Results: Authors can presume that sitagliptin use was not related with any dangers and is compelling in the board of Type 2 diabetics, treatment with sitagliptin gave clinically significant decreases in HbA1C, RBS, FBS, PPBS by utilizing this investigation authors realize that gliptins are considerably more protected and powerful in the treatment of sort 2 diabetes mellitus.

Conclusion: Treatment with sitagliptin provided clinically meaningful reductions in HbA1C, RBS, FBS, PPBS by using this study authors know that sitagliptins are much more safe and effective in the treatment of type 2 diabetes mellitus.


Diabetes mellitus, FBS, Glycosylated hemoglobin, Insulin, PPBS, RBS, Sitagliptin

Full Text:



Diabetes Blue Circle Symbol. International Diabetes Federation. 17 March 2006. Available at: Accessed on 11 Aug 2016.

Diabetes Fact sheet N°312. WHO. October 2013. Available at: 26 August 2013. Accessed on 06 Sep 2019.

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 32(7):1335-43.

Chiang JL, Kirkman MS, Laffel LMB, Peters AL Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. Diabetes Care. 37(7):2034-54.

Causes of Diabetes. National Institute of Diabetes and Digestive and Kidney Diseases. June 2014. Accessed on 10 February 2016.

Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician. 2009 Jan 1;79(1):29-36.

Brutsaert EF. Albert Einstein College of Medicine, Drug Treatment of Diabetes Mellitus, January 2019 by Erika F. Brutsaert, MD.

Bell DS. A Comparison of agents used to manage type 2 diabetes mellitus: Need for reappraisal of traditional approaches. Treat Endocrinol. 2004;3(2):67-76.

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-72.

De Fronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulindependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541-9.

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Diabetes Study Group. Diabetes Care. 1998;21(1):87-92.

Shah SK, Saikia M, Burman NN, Snehalatha A. Risk factors of type 2 diabetes in urban population in north eastern India. Int J Diabetes Dev Countries 1999;19:144-7.

Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B, et al., Moderate Obesity and Type 2 Diabetes: Analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013 Aug 1;36(8):2175-82.

International Diabetes Federation. Diabetes and Cardiovascular Disease. 2016. Available at; Accessed on 27 Oct 2016.

Srivastava S, Saxena GN, Keshwani P, Gupta R. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. JAPI. 2012;60(2):27-30.

Anjoom M, Dutta S, Beg MA, Varma A, Bawa S, Kant R. Comparative evaluation of combination of metformin and glimepiride with that of metformin and sitagliptin in type 2 diabetes mellitus with respect to glycemic targets. Int J Med Sci Public Health. 2015;4(4):476-80.

Hayati F, Hazim A, Sasongko TH, Siew HG, Wan WMI, Daud J, et al. Efficacy and safety of sitagliptin as a third therapeutic agent in the treatment of type 2 diabetes mellitus. J Diab Res Clin Met. 2014;3(1):10.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metabol. 2006 Nov 1;91(11):4612-9.

Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Practice. 2007 Jan;61(1):171-80.

Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006 Nov 1;49(11):2564-71.

Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2007 Mar;9(2):186-93.

Nauck MA, Meininger G, Sheng D et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non- inferiority trial. Diabetes Obes Metab. 2007;9(2):194-205.